^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer

    Published date:
    05/23/2016
    Excerpt:
    Targeted Therapy: Exemestane and everolimus may be offered to postmenopausal women with HR-positive MBC who experienced during prior treatment with nonsteroidal AIs with or without one line of prior chemotherapy, either before or after treatment with fulvestrant, because PFS but not OS was improved compared with exemestane alone.
    Secondary therapy:
    exemestane
    DOI:
    10.1200/JCO.2016.67.1487
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Negative Breast Cancer)
    New
    Excerpt:
    Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dose EScalation Induction of EvERolimus

    Excerpt:
    ...symptomatic visceral metastasis) -Histological confirmed hormone receptor-positive (HR+), HER2- negative carcinoma of the breast....
    Trial ID:
    Desiree
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

    Excerpt:
    ...- Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER2 negative invasive breast carcinoma....
    Trial ID:
    NCT02236572
    More C2 evidence